IMUC (EOM Pharmaceutical Holdings) Cyclically Adjusted PB Ratio: (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is EOM Pharmaceutical Holdings Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


EOM Pharmaceutical Holdings  (OTCPK:IMUC) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


EOM Pharmaceutical Holdings Cyclically Adjusted PB Ratio Related Terms


EOM Pharmaceutical Holdings Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for EOM Pharmaceutical Holdings's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EOM Pharmaceutical Holdings Cyclically Adjusted PB Ratio Chart

EOM Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

EOM Pharmaceutical Holdings Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IMUC vs MNTMD, RTTR, BZYR: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, EOM Pharmaceutical Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EOM Pharmaceutical Holdings Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where EOM Pharmaceutical Holdings's Cyclically Adjusted PB Ratio falls into.



EOM Pharmaceutical Holdings Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

EOM Pharmaceutical Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2018 is calculated as:

For example, EOM Pharmaceutical Holdings's adjusted Book Value per Share data for the three months ended in Jun. 2018 was:

Adj_Book=Book Value per Share/CPI of Jun. 2018 (Change)*Current CPI (Jun. 2018)
=0.818/251.9890*251.9890
=0.818

Current CPI (Jun. 2018) = 251.9890.

EOM Pharmaceutical Holdings Quarterly Data

Book Value per Share CPI Adj_Book
200809 109.938 218.783 126.624
200812 91.875 210.228 110.126
200903 75.563 212.709 89.517
200906 57.730 215.693 67.445
200909 49.432 215.969 57.676
200912 29.649 215.949 34.597
201003 44.214 217.631 51.194
201006 87.491 217.965 101.148
201009 68.887 218.439 79.467
201012 41.714 219.179 47.958
201103 69.286 223.467 78.129
201106 54.380 225.722 60.708
201109 63.282 226.889 70.283
201112 44.889 225.672 50.124
201203 66.837 229.392 73.421
201206 23.208 229.478 25.485
201209 29.379 231.407 31.992
201212 178.822 229.601 196.259
201303 142.853 232.773 154.646
201306 170.719 233.504 184.234
201309 177.331 234.149 190.842
201312 183.847 233.049 198.788
201403 163.167 236.293 174.006
201406 163.967 238.343 173.355
201409 154.164 238.031 163.204
201412 146.491 234.812 157.207
201503 143.226 236.119 152.852
201506 130.261 238.638 137.549
201509 116.327 237.945 123.193
201512 96.106 236.525 102.389
201603 72.183 238.132 76.383
201606 50.991 241.018 53.312
201609 33.811 241.428 35.290
201612 17.826 241.432 18.605
201703 1.388 243.801 1.435
201706 -8.273 244.955 -8.511
201709 -0.220 246.819 -0.225
201712 1.109 246.524 1.134
201803 0.876 249.554 0.885
201806 0.818 251.989 0.818

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


EOM Pharmaceutical Holdings Business Description

Address 136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is a clinical-stage biotechnology company that is focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases. Its products have been approved in the U.S., rheumatoid arthritis, and inflammatory conditions of the gastrointestinal tract such as Crohn's Disease and Ulcerative Colitis as well as various retina disorders characterized by a breakdown of the blood-retinal barrier such as diabetic retinopathy, Aged related macular degeneration and retinal vein occlusion among others. Its pipeline includes its compound EOM613, an investigational novel dynamically dual-acting immunomodulator.